KF-1602

N/A

Report date: 2024/12/18 13:39:48
NME

Base Information

Drug NameKF-1602
Drug Alias NameKF-1602
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLung NeoplasmsThyroid Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImmunoForge Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsThyroid Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A